Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 452

1.

Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.

Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL, Roth K, Zhai Y, Huss K, Kuo MS, Gillig J, Parthasarathy S, Burkholder TP, Smith MC, Geeganage S, Zhao G.

J Biol Chem. 2013 Feb 1;288(5):3500-11. doi: 10.1074/jbc.M112.394510. Epub 2012 Dec 13.

2.

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.

Tan B, Dong S, Shepard RL, Kays L, Roth KD, Geeganage S, Kuo MS, Zhao G.

J Biol Chem. 2015 Jun 19;290(25):15812-24. doi: 10.1074/jbc.M114.632141. Epub 2015 May 5.

3.

Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.

Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.

Cancer Lett. 2016 Aug 28;379(1):1-11. doi: 10.1016/j.canlet.2016.05.024. Epub 2016 May 24.

PMID:
27233476
4.

Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells.

Tolstikov V, Nikolayev A, Dong S, Zhao G, Kuo MS.

PLoS One. 2014 Dec 8;9(12):e114019. doi: 10.1371/journal.pone.0114019. eCollection 2014.

5.

FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.

Schuster S, Penke M, Gorski T, Gebhardt R, Weiss TS, Kiess W, Garten A.

Biochem Biophys Res Commun. 2015 Mar 6;458(2):334-40. doi: 10.1016/j.bbrc.2015.01.111. Epub 2015 Feb 3.

PMID:
25656579
6.

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.

Moore Z, Chakrabarti G, Luo X, Ali A, Hu Z, Fattah FJ, Vemireddy R, DeBerardinis RJ, Brekken RA, Boothman DA.

Cell Death Dis. 2015 Jan 15;6:e1599. doi: 10.1038/cddis.2014.564.

7.

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S, Christensen MK, Fristrup P, Thougaard AV, Björkling F, Jensen PB, Nielsen SJ, Sehested M.

BMC Cancer. 2010 Dec 12;10:677. doi: 10.1186/1471-2407-10-677.

8.

Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool.

Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F, Romano G, Moneti G, Moroni F, Chiarugi A.

J Biol Chem. 2010 Oct 29;285(44):34106-14. doi: 10.1074/jbc.M110.136739. Epub 2010 Aug 19.

9.

CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Grozio A, Sociali G, Sturla L, Caffa I, Soncini D, Salis A, Raffaelli N, De Flora A, Nencioni A, Bruzzone S.

J Biol Chem. 2013 Sep 6;288(36):25938-49. doi: 10.1074/jbc.M113.470435. Epub 2013 Jul 23.

10.

Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.

Okumura S, Sasaki T, Minami Y, Ohsaki Y.

J Thorac Oncol. 2012 Jan;7(1):49-56. doi: 10.1097/JTO.0b013e318233d686.

11.

Nampt/PBEF/visfatin and cancer.

Bi TQ, Che XM.

Cancer Biol Ther. 2010 Jul 15;10(2):119-25. doi: 10.4161/cbt.10.2.12581. Epub 2010 Jul 3. Review.

PMID:
20647743
12.

Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.

Sociali G, Raffaghello L, Magnone M, Zamporlini F, Emionite L, Sturla L, Bianchi G, Vigliarolo T, Nahimana A, Nencioni A, Raffaelli N, Bruzzone S.

Oncotarget. 2016 Jan 19;7(3):2968-84. doi: 10.18632/oncotarget.6502.

13.

Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Chini CC, Guerrico AM, Nin V, Camacho-Pereira J, Escande C, Barbosa MT, Chini EN.

Clin Cancer Res. 2014 Jan 1;20(1):120-30. doi: 10.1158/1078-0432.CCR-13-0150. Epub 2013 Sep 11.

14.

NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.

Hong SM, Park CW, Kim SW, Nam YJ, Yu JH, Shin JH, Yun CH, Im SH, Kim KT, Sung YC, Choi KY.

Oncogene. 2016 Jul 7;35(27):3544-54. doi: 10.1038/onc.2015.415. Epub 2015 Nov 16.

PMID:
26568303
15.

Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.

Montecucco F, Cea M, Bauer I, Soncini D, Caffa I, Lasigliè D, Nahimana A, Uccelli A, Bruzzone S, Nencioni A.

Curr Drug Targets. 2013 Jun 1;14(6):637-43. Review.

PMID:
23531116
16.

EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.

Zucal C, D'Agostino VG, Casini A, Mantelli B, Thongon N, Soncini D, Caffa I, Cea M, Ballestrero A, Quattrone A, Indraccolo S, Nencioni A, Provenzani A.

BMC Cancer. 2015 Nov 5;15:855. doi: 10.1186/s12885-015-1845-1.

17.

Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.

Wang LF, Wang XN, Huang CC, Hu L, Xiao YF, Guan XH, Qian YS, Deng KY, Xin HB.

Lipids Health Dis. 2017 Apr 27;16(1):82. doi: 10.1186/s12944-017-0464-z.

19.

NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.

Zhang XQ, Lu JT, Jiang WX, Lu YB, Wu M, Wei EQ, Zhang WP, Tang C.

Neuroscience. 2015 Apr 16;291:230-40. doi: 10.1016/j.neuroscience.2015.02.007. Epub 2015 Feb 12.

PMID:
25684751
20.

NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.

Burgos ES.

Curr Med Chem. 2011;18(13):1947-61. Review.

PMID:
21517777

Supplemental Content

Support Center